Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenal Cortex Neoplasms | 1 | 2017 | 5 | 0.600 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2017 | 6 | 0.600 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 27 | 0.600 |
Why?
|
| Lymph Nodes | 1 | 2017 | 71 | 0.570 |
Why?
|
| State Medicine | 1 | 2002 | 2 | 0.210 |
Why?
|
| National Health Programs | 1 | 2002 | 5 | 0.210 |
Why?
|
| Family Practice | 1 | 2002 | 20 | 0.200 |
Why?
|
| Esophageal pH Monitoring | 1 | 2020 | 1 | 0.180 |
Why?
|
| beta-Thalassemia | 2 | 2010 | 3 | 0.170 |
Why?
|
| Hydroxyurea | 2 | 2010 | 29 | 0.170 |
Why?
|
| Survival Rate | 2 | 2018 | 376 | 0.170 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 34 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 79 | 0.160 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 161 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 17 | 0.150 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 1 | 0.150 |
Why?
|
| Antigens, Surface | 1 | 2017 | 27 | 0.150 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 30 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 46 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 38 | 0.150 |
Why?
|
| Fundoplication | 1 | 2017 | 20 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 18 | 0.140 |
Why?
|
| Operative Time | 1 | 2017 | 81 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 297 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 81 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 364 | 0.140 |
Why?
|
| Laparoscopy | 1 | 2017 | 143 | 0.130 |
Why?
|
| Middle Aged | 6 | 2020 | 9953 | 0.130 |
Why?
|
| Aged | 6 | 2020 | 9633 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2017 | 230 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2017 | 213 | 0.110 |
Why?
|
| Male | 8 | 2020 | 15858 | 0.110 |
Why?
|
| Adult | 6 | 2017 | 8731 | 0.110 |
Why?
|
| Trigonella | 1 | 2013 | 1 | 0.110 |
Why?
|
| Female | 8 | 2020 | 16417 | 0.110 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2013 | 2 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2013 | 16 | 0.110 |
Why?
|
| Noise, Occupational | 1 | 2012 | 2 | 0.110 |
Why?
|
| Operating Rooms | 1 | 2012 | 13 | 0.110 |
Why?
|
| Levodopa | 1 | 2013 | 142 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1859 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 43 | 0.100 |
Why?
|
| Humans | 11 | 2020 | 29829 | 0.100 |
Why?
|
| Hemoglobin E | 1 | 2010 | 1 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2010 | 65 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2013 | 1185 | 0.060 |
Why?
|
| Young Adult | 3 | 2017 | 1966 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2002 | 13 | 0.050 |
Why?
|
| Australia | 1 | 2002 | 46 | 0.050 |
Why?
|
| United Kingdom | 1 | 2002 | 51 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2002 | 85 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 1821 | 0.050 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2000 | 3 | 0.050 |
Why?
|
| Multimedia | 1 | 2020 | 1 | 0.040 |
Why?
|
| Comprehension | 1 | 2020 | 28 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 74 | 0.040 |
Why?
|
| Cardia | 1 | 2018 | 2 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 30 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2018 | 25 | 0.040 |
Why?
|
| Esophagectomy | 1 | 2018 | 22 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 65 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 53 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 78 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 95 | 0.040 |
Why?
|
| Microvessels | 1 | 2017 | 16 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 87 | 0.040 |
Why?
|
| Mutation | 2 | 2010 | 396 | 0.040 |
Why?
|
| New York City | 1 | 2017 | 18 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 43 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2018 | 331 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 198 | 0.030 |
Why?
|
| Child | 2 | 2010 | 1376 | 0.030 |
Why?
|
| Adolescent | 2 | 2010 | 2331 | 0.030 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2013 | 7 | 0.030 |
Why?
|
| Seeds | 1 | 2013 | 7 | 0.030 |
Why?
|
| Extracorporeal Circulation | 1 | 2012 | 1 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2012 | 8 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2012 | 40 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2012 | 30 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2013 | 520 | 0.020 |
Why?
|
| United States | 1 | 2018 | 2344 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2010 | 3557 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2010 | 3 | 0.020 |
Why?
|
| beta-Globins | 1 | 2010 | 5 | 0.020 |
Why?
|
| Ferritins | 1 | 2010 | 9 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2009 | 1 | 0.020 |
Why?
|
| Hematology | 1 | 2009 | 2 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2009 | 6 | 0.020 |
Why?
|
| India | 1 | 2009 | 21 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 59 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 376 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 400 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 3325 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 325 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 4941 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 282 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 654 | 0.020 |
Why?
|
| Pakistan | 1 | 2000 | 1 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2000 | 135 | 0.010 |
Why?
|